Advertisement

Tumor Biology

, Volume 37, Issue 1, pp 47–55 | Cite as

Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy

  • Yousaf Ali
  • Shafida Abd Hamid
Review

Abstract

Topoisomerases are nuclear enzymes that regulate topology of DNA by facilitating the temporary cleavage and ligation cycle of DNA. Among all forms of topoisomerases, TOP-IIA is extensively associated with cell proliferation and therefore is an important therapeutic target in diseases that involved cellular proliferation such as cancers. Nearly half of present-day antitumor regimens contain at least one prescription that act as a topoisomerase inhibitor. Generally, tumor cells show divergent expression of TOP-IIA compared to normal cells. The remarkable expression of TOP-IIA in various carcinomas provides a significant biomarker toward understanding the nature of malignancy. TOP-IIA expression and amplification studies help in diagnosing cancer and to observe the disease progression, overall survival (OS) of patients, and response to therapy. This review highlights the research output and analysis in exploring the standing of TOP-IIA in various carcinomas. As some reports show contradiction within the same field of interest, the outline of that may help to induce researchers for further investigation and clarification. To the best of our knowledge, this is the first overview briefly summarizing the prognostic feature of TOP-IIA in various types of cancer.

Keywords

Topoisomerase II alpha Prognosis Biomarker Cancer 

Notes

Acknowledgments

The authors gratefully acknowledge The Ministry of Science, Technology, and Innovation MOSTI Malaysia (06-01-08-SF0147) for supporting the research team.

Compliance of ethical standards

Conflicts of interest

None

References

  1. 1.
    Bromberg KD, Osheroff N. Mechanism of action of topoisomerase II-targeted anticancer drugs. DNA Topoisomerases in Cancer Therapy: Springer; 2003. p. 53–78.Google Scholar
  2. 2.
    Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65(1):635–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Thakur DS. Topoisomerase II, inhibitors in cancer treatment. Int J Pharm Sci Nanotechnol. 2011;3(4):1173–81.Google Scholar
  4. 4.
    Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70(1):369–413.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang JC. Reflections on an accidental discovery. DNA Topoisomerases in Cancer Therapy: Springer; 2003. p. 1–13.Google Scholar
  6. 6.
    Pommier Y, Barceló J, Furuta T, Takemura H, Sordet O. Mechanisms of topoisomerase I inhibition by anticancer drugs. DNA Topoisomerases in Cancer Therapy: Springer; 2003. p. 15–52.Google Scholar
  7. 7.
    Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases i. Biochim Biophys Acta Gene Struct Expr. 1995;1262(1):1–14.CrossRefGoogle Scholar
  8. 8.
    Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Higgins NP. A human TOP2A core DNA binding X-ray structure reveals topoisomerase subunit dynamics and a potential mechanism for SUMO modulation of decatenation. J Mol Biol. 2012;424(3):105–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Lin Y-S, Huang W-C, Chen M-S, Hsieh T-s. Toward discovering new anti-cancer agents targeting topoisomerase IIα: a facile screening strategy adaptable to high throughput platform. 2014.Google Scholar
  11. 11.
    Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta Gene Struct Expr. 1998;1400(1):155–71.CrossRefGoogle Scholar
  12. 12.
    Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer. 2009;9(5):327–37.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res. 2001;80:189–216.PubMedCrossRefGoogle Scholar
  14. 14.
    Wu S-Y, Pan S-L, Xiao Z-Y, Hsu J-L, Chen M-C, Lee K-H, et al. NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and Ros generation in human renal carcinoma cells. 2014.Google Scholar
  15. 15.
    Hajji N, Pastor N, Mateos S, Cortés F. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. Mutat Res Fundam Mol Mech Mutagen. 2003;530(1):35–46.CrossRefGoogle Scholar
  16. 16.
    Shastry B. Overexpression of genes in health and sickness. A bird’s eye view. Comp Biochem Physiol B Biochem Mol Biol. 1995;112(1):1–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol. 2012;424(3):109–24.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Belluti S, Basile V, Benatti P, Ferrari E, Marverti G, Imbriano C. Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells. Cell Death Dis. 2013;4(8):e756.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Kim E-J, Lee Y-S, Kim Y-J, Kim M-J, Ha Y-S, Jeong P, et al. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology. 2010;75(6):1516.e9–13.CrossRefGoogle Scholar
  20. 20.
    Davies SL, Popert R, Coptcoat M, Hickson ID, Masters JR. Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II α and β genes. Int J Cancer. 1996;65(1):63–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Koren R, Kugel V, Dekel Y, Weissman Y, Livne P, Gal R. Human DNA topoisomerase‐IIα expression as a prognostic factor for transitional cell carcinoma of the urinary bladder. BJU Int. 2003;91(6):489–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, et al. HER‐2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 2003;107(5):764–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Ben Abdelkrim S, Rammeh S, Ziadi S, Tlili T, Jaidane M, Mokni M. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma. J Immunoass Immunochem. 2014;35(4):358–67.CrossRefGoogle Scholar
  24. 24.
    Monnin KA, Bronstein IB, Gaffney DK, Holden JA. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol. 1999;30(4):384–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Van der Zee A, De Vries E, Hollema H, Kaye S, Brown R, Keith WN. Molecular analysis of the topoisomerase II α gene and its expression in human ovarian cancer. Ann Oncol. 1994;5(1):75–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, et al. Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol. 2009;22(4):579–88.PubMedCrossRefGoogle Scholar
  27. 27.
    Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, et al. Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients. Br J Cancer. 2008;98(12):1910–5.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocellular Carcinoma. 2014;1:115–25.CrossRefGoogle Scholar
  29. 29.
    Wong N, Yeo W, Wong WL, Wong NLY, Chan KYY, Mo FKF, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124(3):644–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, Kikuchi A, et al. Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Res. 2001;22(2B):1113–9.Google Scholar
  31. 31.
    Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S. TOP2A amplification and overexpression in hepatocellular carcinoma tissues. BioMed Res Int. 2015;2015.Google Scholar
  32. 32.
    Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang J-M, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res. 1998;4(6):1393–403.PubMedGoogle Scholar
  33. 33.
    Willman JH, Holden JA. Immunohistochemical staining for DNA topoisomerase II‐alpha in benign, premalignant, and malignant lesions of the prostate. Prostate. 2000;42(4):280–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Hughes C, Murphy A, Martin C, Fox E, Ring M, Sheils O, et al. Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol. 2006;59(7):721–4.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O’Leary JJ, et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 2007;67(6):2893–8.PubMedCrossRefGoogle Scholar
  36. 36.
    De Resende MF, Vieira S, Chinen L, Chiappelli F, da Fonseca FP, Guimarães GC, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11(1):1–9.CrossRefGoogle Scholar
  37. 37.
    Hasby E, Saied E. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia. J Egypt Natl Canc Inst. 2008;20(2):158–67.PubMedGoogle Scholar
  38. 38.
    da Cunha IW, De Brot L, Carvalho KC, Rocha RM, Fregnani JH, Falzoni R, et al. Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin. Ann Surg Oncol. 2012;19(6):1790–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG. Expression of E-cadherin, β-catenin and topoisomerase IIα in leiomyosarcomas. Clin Transl Oncol. 2009;11(8):548–51.PubMedCrossRefGoogle Scholar
  40. 40.
    Ptaszyński K, Szumera-Ciećkiewicz A, Zakrzewska K, Tuziak T, Mrozkowiak A, Rutkowski P. HER2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment. Pol J Pathol. 2009;1:10–8.Google Scholar
  41. 41.
    Endo H, Hirokawa M, Ishimaru N, Tanaka Y, Yamashita M, Sakaki M, et al. Unique cell membrane expression of topoisomerase‐II alpha as a useful diagnostic marker of liposarcoma. Pathol Int. 2004;54(3):145–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhao H, Yu H, Liu Y, Wang Y, Cai W. DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival. Clin Neuropathol. 2007;27(2):83–90.Google Scholar
  43. 43.
    Hong Y, Sang M, Shang C, Xue Y-x, Liu Y-h. Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells. Neurosci Lett. 2012;518(2):138–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Miettinen H, Järvinen T, Kellner U, Kauraniemi P, Parwaresch R, Rantala I, et al. High topoisomerase IIα expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol. 2000;26(6):504–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Shamaa AA, Zyada MM, Wagner M, Awad SS, Osman MM, Azeem AAA. The significance of Epstein Barr virus (EBV) & DNA topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). Diagn Pathol. 2008;3:45.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Hanagiri T, Ono K, Kuwata T, Takenaka M, Oka S, Chikaishi Y, et al. Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer. J UOEH. 2011;33(3):205–16.PubMedCrossRefGoogle Scholar
  47. 47.
    Xu X-L, Zheng W-H, Fu Z-X, Li Z-P, Xie H-X, Li X-X, et al. Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas. Med Oncol. 2015;32(1):1–9.CrossRefGoogle Scholar
  48. 48.
    Ohashi Y, Sasano H, Yamaki H, Shizawa S, Kikuchi A, Shineha R, et al. Topoisomerase II alpha expression in esophageal squamous cell carcinoma. Anticancer Res. 1998;19(3A):1873–80.Google Scholar
  49. 49.
    Lan J, Huang H-Y, Lee S-W, Chen T-J, Tai H-C, Hsu H-P, et al. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumor Biol. 2014;35(1):179–87.CrossRefGoogle Scholar
  50. 50.
    Feng Y, Zhang H, Gao W, Wen S, Huangfu H, Sun R, et al. Expression of DNA topoisomerase II-α: clinical significance in laryngeal carcinoma. Oncol Lett. 2014;8(4):1575–80.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Chiu C-F, Chow K-C, Lin F-M, Lin CK, Liu S-M, Chen KY. Expression of DNA topoisomerase IIα and multidrug resistance p-glycoprotein in acute leukemia. Chin Med J (Taipei). 1997;60:184–90.Google Scholar
  52. 52.
    Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, Korkolopoulou P, Angelopoulou MK, Siakantaris MP, et al. Topoisomerase IIα expression as an independent prognostic factor in Hodgkin’s lymphoma. Clin Cancer Res. 2008;14(6):1759–66.PubMedCrossRefGoogle Scholar
  53. 53.
    Tretiakova M, Turkyilmaz M, Grushko T, Kocherginsky M, Rubin C, Teh B, et al. Topoisomerase IIα in Wilms’ tumour: gene alterations and immunoexpression. J Clin Pathol. 2006;59(12):1272–7.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Tsiambas E, Karameris A, Tiniakos DG, Karakitsos P. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays. Pancreatology. 2007;7(1):45–52.PubMedCrossRefGoogle Scholar
  55. 55.
    Liang Z, Wang W, Gao J, Wu S, Zeng X, Liu T. Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas. Zhonghua Bing Li Xue Za Zhi Chin J Pathol. 2007;36(2):102–6.Google Scholar
  56. 56.
    Manaios L, Tsiambas E, Alevizaki M, Karameris A, Alexopoulou D, Lambropoulou S, et al. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis. J BUON. 2007;13(4):537–41.Google Scholar
  57. 57.
    Yan S, Shun-Chang J, Li C, Jie L, Ya-Li L, Ling-Xiong W. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer. 2010;10(1):621.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann J, Janssen D, et al. Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004;18(7):1200–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Argani P, et al. Topoisomerase II α status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol. 2009;182(2):735–40.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase‐inhibiting therapy. BJU Int. 2010;106(1):62–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Jain M, Zhang L, He M, Zhang Y-Q, Shen M, Kebebew E. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(3):361–70.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Stromar IK, Jakic-Razumovic J. The value of immunohistochemical determination of topoisomerase iiα and ki67 as markers of cell proliferation and malignant transformation in colonic mucosa. Appl Immunohistochem Mol Morphol. 2014;22(7):524–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Kim R, Ohi Y, Inoue H, Toge T. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res. 1998;19(6B):5393–8.Google Scholar
  64. 64.
    Yang F, Jia Z. Expression of topoisomerase II alpha in human colorectal carcinoma and its significance. Nan fang yi ke da xue xue bao J South Med Univ. 2010;30(8):1959–61. 64.Google Scholar
  65. 65.
    Liming S, Yuan Z, Qinghua D, Lei W, Qifeng J, Haojie L. Human epidermal growth factor receptor-2 and topoisomerase II alpha expressions in rectal cancer. Hepatogastroenterology. 2010;58(106):359–63.Google Scholar
  66. 66.
    Gao XH, Yu ZQ, Zhang C, Bai CG, Zheng JM, Fu CG. DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner. Int J Colorectal Dis. 2012;27(4):429–35.PubMedCrossRefGoogle Scholar
  67. 67.
    Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer. 2004;109(4):548–53.PubMedCrossRefGoogle Scholar
  68. 68.
    Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A. Topoisomerase IIα gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006;37(10):1333–43.PubMedCrossRefGoogle Scholar
  69. 69.
    Tanner M, Hollmen M, Junttila T, Kapanen A, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Liu H-Q, Zhang S-L, Song S. HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity. Hepatogastroenterology. 2012;59(116):1290–3.PubMedGoogle Scholar
  71. 71.
    Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol. 2009;14(2):112–9.PubMedCrossRefGoogle Scholar
  72. 72.
    El Rebey HS, Aiad HA, Asaad NY, Abd El-Wahed MM, Abulkheir IL, Abulkasem FM, et al. Immunohistochemical expression of topoisomerase II a and tissue inhibitor of metalloproteinases 1 in locally advanced breast carcinoma. Menoufia Med J. 2014;27(1):1.CrossRefGoogle Scholar
  73. 73.
    Huang L, Chen T, Chen C, Chen S, Liu Y, Wu J, et al. Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. World J Surg Oncol. 2013;11(1):1–9.CrossRefGoogle Scholar
  74. 74.
    Mrklic I, Pogorelic Z, Capkun V, Tomic S. Expression of topoisomerase II-α in triple negative breast cancer. Appl Immunohistochem Mol Morphol. 2014;22(3):182–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Żaczek A, Markiewicz A, Supernat A, Bednarz-Knoll N, Brandt B, Seroczyńska B, et al. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathol Oncol Res. 2012;18(4):885–94.PubMedCrossRefGoogle Scholar
  76. 76.
    Zhu L, Li Y-F, Chen W-G, He J-R, Peng C-H, Zhu Z-G, et al. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J. 2008;121(20):1965–8.PubMedGoogle Scholar
  77. 77.
    Biesaga B, Niemiec J, Ziobro M, Wysocka J, Kruczak A. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy. Breast. 2011;20(4):338–50.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Kulliyyah of ScienceInternational Islamic University MalaysiaKuantanMalaysia

Personalised recommendations